Barclays Begins Coverage on Repligen (NASDAQ:RGEN)

Barclays began coverage on shares of Repligen (NASDAQ:RGEN - Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm issued an overweight rating and a $150.00 price objective on the biotechnology company's stock.

A number of other research firms have also commented on RGEN. Royal Bank Of Canada decreased their price target on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Evercore ISI started coverage on Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price on the stock. Wall Street Zen raised Repligen from a "hold" rating to a "buy" rating in a report on Saturday, June 21st. HC Wainwright reiterated a "buy" rating and set a $180.00 price target on shares of Repligen in a research report on Monday, May 5th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $172.83.

Repligen Price Performance

Shares of NASDAQ:RGEN traded down $1.42 on Tuesday, hitting $122.79. The stock had a trading volume of 216,043 shares, compared to its average volume of 727,677. The firm's 50 day moving average price is $128.22 and its 200-day moving average price is $141.22. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. Repligen has a twelve month low of $102.97 and a twelve month high of $182.52. The company has a market capitalization of $6.90 billion, a price-to-earnings ratio of -272.79, a price-to-earnings-growth ratio of 3.55 and a beta of 1.10.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. The firm had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The company's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.28 earnings per share. On average, equities research analysts predict that Repligen will post 1.72 earnings per share for the current year.

Hedge Funds Weigh In On Repligen

Several large investors have recently bought and sold shares of the business. Signaturefd LLC grew its holdings in Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 124 shares during the period. Sava Infond d.o.o. acquired a new stake in shares of Repligen during the fourth quarter worth $29,000. Raiffeisen Bank International AG bought a new stake in Repligen in the fourth quarter valued at about $29,000. Twin Tree Management LP acquired a new position in Repligen in the first quarter valued at about $29,000. Finally, Itau Unibanco Holding S.A. bought a new position in Repligen during the fourth quarter worth about $40,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.